fbpx
SKIP TO MAIN CONTENT

TSC Alert

Archive for April, 2022

TSC Alliance® Partners with NeurologyLive™

The TSC Alliance has partnered with NeurologyLive to bring healthcare professionals treating neurological disorders the latest in research and practice. Check out our partner page. Subscribe to NeurologyLive to stay up to date on clinical trial news, FDA updates and more.

Research Study on TSC and COVID-19

The TSC Alliance is collecting clinical information about individuals with TSC who were infected with COVID-19. Please circulate the following to your patients: The TSC Alliance is collecting clinical information in their TSC Natural History Database about individuals with TSC who were infected with COVID-19. TSC researchers will use this information to help determine how medications such as everolimus (Afinitor®, Zortress®) or sirolimus (Rapamune®) and other TSC conditions affect the risk of getting COVID-19 and its severity. If you or your loved one with TSC had COVID-19 confirmed by testing, please consider participating in the TSC Alliance Natural History Database….

Join Our Peer-to-Peer Listserv for Healthcare Professionals

The TSC Alliance invites healthcare professionals affiliated with a TSC Clinic, TSC Center of Excellence, or University Medical Center to subscribe to our private listserv: p2p@lists.tscalliance.org. Its primary purpose is for members to pose TSC-related cases or questions to their peers for feedback. Members may also use the listserv to seek opportunities for collaboration on TSC-related projects. The listserv is monitored to ensure it is being used for appropriate communications.

TANDem Seed Grant Funding Available from UK Tuberous Sclerosis Association

  |  Grants

This year, together with the TAND consortium, The Tuberous Sclerosis Association in the UK is running their first ever TAND-centered funding round. The remit of this call is to offer small ‘seed’ grants (€2,000-€10,000 per award) to international researchers, in particular early career investigators (up to 10 years post PhD).